Forteo ® (teriparatide [rDNA origin] injection)

20-mcg daily dose in a 2.4-mL prefilled delivery device

The below information is provided in response to your request and may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above.

BMD Response with FORTEO® (teriparatide [rDNA origin] injection) Treatment

Forteo significantly increased lumbar spine, femoral neck, and total hip BMD from baseline in PMW and men with osteoporosis and in patients with GIO

Effects of teriparatide on BMD in postmenopausal women with osteoporosis

Results from a last observation carried forward (LOCF) analysis showed that FORTEO® (teriparatide [rDNA origin] injection) significantly increased baseline to endpoint bone mineral density (BMD) at the

  • lumbar spine (9.7%),

  • femoral neck (2.8%), and

  • total hip (2.6%) (Table 1) (Forteo Package Insert, 2012).

In a subset of women for whom data were available at every time point (3, 6, 12, and 18 months), teriparatide significantly increased lumbar spine BMD by 3.9% at 3 months of treatment and 11.8% at 18 months (Forteo Package Insert, 2012).

Effects of teriparatide on BMD in men with primary or hypogonadal osteoporosis

Using a LOCF analysis, results showed that teriparatide treatment, for a median of 10 months, significantly increased baseline lumbar spine BMD by 5.9% compared to placebo (p<.001). Significant increases in lumbar spine BMD were seen at 3 months (Forteo Package Insert, 2012).

Teriparatide treatment significantly increased femoral neck BMD by 1.5% from baseline compared to the placebo group (p<.05) (Forteo Package Insert, 2012).

There was no significant difference observed in the change from baseline to endpoint total hip BMD (Forteo Package Insert, 2012).

Effects of teriparatide on BMD in men and women with glucocorticoid-induced osteoporosis

Results from a LOCF analysis showed that teriparatide significantly increased baseline to endpoint BMD at the lumbar spine, femoral neck, and total hip by 7.2%, 3.6%, and 3.7%, respectively, at the 18 month endpoint (p<.001 all sites) (Forteo Package Insert, 2012).

Table 1. Mean Percentage Change in BMD from Baseline to Endpointa in Postmenopausal Women with Osteoporosis Treated with Teriparatide for a Median of 19 Months (Forteo Package Insert, 2012)

Abbreviations: BMD = bone mineral density

a Intent-to-treat analysis, last observation carried forward

b p<.001 compared with placebo

c p<.05 compared with placebo

Enclosed Prescribing Information

FORTEO® (teriparatide [rDNA origin] injection), Lilly

The published references below are available upon request by contacting 1-800-LillyRx.

References

FORTEO® [Package Insert]. Indianapolis, IN: Eli Lilly and Company; 2012.

Date of Last Review: February 12, 2017

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 9am - 8pm ET

Or you can

Ask us a question Chat with us

Submit a question

Visit Us @LillyMedical